Ancestim (r-metHuSCF) in combination with filgrastim to rescue mobilization and collection of peripheral blood progenitor cells for autologous transplantation. Compassionate use in 288 patients at 62 sites in France (1998-2003).


6642 Background: Approximately 15% of patients (pts) eligible for HDC and peripheral blood progenitor cell (PBPC) transplantation, failed to generate an adequate PBPC graft. METHODS Ancestim (r-metHuSCF, Amgen, Thousand Oaks, CA) was delivered on a named-pt basis under the French Temporary Authorization for Use program to 288 pts with prior failure to… (More)


  • Presentations referencing similar topics